Update: use of the benchmark dose approach in risk assessment¶
EFSA Scientific Committee. (2017). Update: use of the benchmark dose approach in risk assessment.
Cited by¶
1 citation across 1 artifact.
Each citation links to the sentence it supports in the citing article.
Domain-specific¶
- NOAEL (No Observed Adverse Effect Level)
- Modern alternatives to the NOAEL/LOAEL approach, particularly the benchmark dose (BMD) method endorsed by international regulatory bodies, fit a dose-response model to the full dataset and derive a dose producing a predetermined small response (typically 1% or 10% above background), which is more statistically stable and uses all the data rather than categorising doses as binary pass/fail
This sourceEFSA's reconfirmation that the benchmark dose approach is 'a scientifically more advanced method compared to the NOAEL approach for deriving a Reference Point', with dose-response models fitted to the dataset and the BMD confidence interval reported; it does not state the 1%-or-10% benchmark response the sentence quotes.
- Modern alternatives to the NOAEL/LOAEL approach, particularly the benchmark dose (BMD) method endorsed by international regulatory bodies, fit a dose-response model to the full dataset and derive a dose producing a predetermined small response (typically 1% or 10% above background), which is more statistically stable and uses all the data rather than categorising doses as binary pass/fail
Verification¶
This reference passed the adversarial substantiation pipeline: it was checked to exist and to support the claim it is attached to. See how references were verified.
Registry ID ref:e8e6e90ef4b6 · see in the full table